Cover Image

Real‐world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience

Abstract Tyrosine kinase inhibitors (TKI) have revolutionized the treatment of chronic myeloid leukemia (CML), but patients still experience treatment‐limiting toxicities or therapeutic failure. To investigate the real‐world use and outcomes of imatinib in patients with CML in Australia, a retrospec...

Full description

Saved in:

Bibliographic Details
Main Authors:	Josephine A. Adattini (Author), Annette S. Gross (Author), Nicole Wong Doo (Author), Andrew J. McLachlan (Author)
Format:	Book
Published:	Wiley, 2022-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Application of physiologically based pharmacokinetic modeling to understand real‐world outcomes in patients receiving imatinib for chronic myeloid leukemia
by: Josephine A. Adattini, et al.
Published: (2023)

Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea
by: Parveen Jain, et al.
Published: (2013)

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
by: Alexandra Rodrigues Alves, et al.

Imatinib-induced extensive hyperpigmentation in a case of chronic myeloid leukemia
by: Pradeep Balasubramanian, et al.
Published: (2015)

Imatinib associated discoid lupus erythematosus in a patient with chronic myeloid leukemia
by: Priya Sarlashkar, BS, et al.
Published: (2024)

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
by: Ronan Swords, et al.
Published: (2009)

Effects of Trough Concentration and Solute Carrier Polymorphisms on Imatinib Efficacy in Chinese Patients with Chronic Myeloid Leukemia
by: Qing Wang, et al.
Published: (2020)

Multiple eruptive dermatofibromas secondary to imatinib mesylate in a patient with chronic myeloid leukemia
by: Francisco J Lira-Valero, et al.
Published: (2021)

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)
by: Martin Henkes, et al.
Published: (2008)

Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients
by: Heriberto Bruzzoni-Giovanelli, et al.
Published: (2024)

Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
by: Aypara Hasanova, et al.
Published: (2023)

Imatinib- and Nilotinib-Induced Lichenoid Eruption in Chronic Myeloid Leukemia: A Rare Case Report
by: Meenakshi Sachdeva, et al.
Published: (2023)

Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia
by: Hyacinthe Johnson-Ansah, et al.
Published: (2022)

Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events
by: Pavel Burda, et al.
Published: (2024)

Profile of imatinib in pediatric leukemia
by: Burke MJ
Published: (2014)

Outcome of pediatric acute myeloid leukemia: Real-world data from a developing Country
by: Ranjitha M, et al.
Published: (2024)

Factors Influencing the Steady-State Plasma Concentration of Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors and Chronic Myeloid Leukemia
by: Yan Chen, et al.
Published: (2020)

The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review
by: Muhammad Darwin Prenggono, et al.
Published: (2021)

Study of correlation between imatinib mesylate plasma levels and hematological profile of patients undergoing treatment for chronic myeloid leukemia
by: Emanuelle S. Dal Ponte, et al.
Published: (2017)

Polymorphisms in Drug Transporter and Metabolism Genes Associated with Resistance to Imatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis
by: Ana Marcela Arrieta Gómez, et al.
Published: (2023)

Assessment of fibrosis and vascularization of bone marrow stroma of chronic myeloid Leukemia patients treated with imatinib mesylate and their relationship with the cytogenetic response
by: Caroline Regina de Jesus, et al.
Published: (2011)

Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma
by: Xiwen Tong, et al.
Published: (2023)

Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics
by: Jeffry Adiwidjaja, et al.
Published: (2020)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
by: Jae Wook Lee, et al.
Published: (2011)

Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo
by: Bharathi M. Rajamani, et al.
Published: (2023)

Long-term imatinib therapy adversely affects bone health in children with chronic myeloid leukemia: A prospective, cross-sectional, descriptive study
by: Srinivasan PP, et al.
Published: (2024)

A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia
by: Dan Liao, et al.
Published: (2019)

Myeloid Leukemia
Published: (2018)

Betulinic Acid-Brosimine B Hybrid Compound Has a Synergistic Effect with Imatinib in Chronic Myeloid Leukemia Cell Line, Modulating Apoptosis and Autophagy
by: Julia Biz Willig, et al.
Published: (2023)

Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
by: Hyun Jin Oh, et al.
Published: (2013)

Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib
by: Gian Paolo Bombeccari, et al.
Published: (2017)

Isolated Ocular Manifestation of Relapsed Chronic Myelogenous Leukemia Presenting as Myeloid Blast Crisis in a Patient on Imatinib Therapy: A Case Report and Review of the Literature
by: Rohit Gulati, et al.
Published: (2015)

PPFIA1-targeting miR-181a mimic and saRNA overcome imatinib resistance in BCR-ABL1-independent chronic myeloid leukemia by suppressing leukemia stem cell regeneration
by: Rui Su, et al.
Published: (2023)

Myeloid Leukemia Clinical Diagnosis and Treatment
Published: (2012)

Myeloid Leukemia Basic Mechanisms of Leukemogenesis
Published: (2011)

The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia
by: Camillo Porta, et al.
Published: (2011)

Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely
by: Ohyashiki JH, et al.
Published: (2014)

Cutaneous myeloid sarcoma associated with chronic myeloid leukemia
by: Erica Rodrigues de Araujo Vasconcelos, et al.
Published: (2017)

Pediatric chronic myeloid leukemia in myeloid blast crisis
by: Biswajit Dey, et al.
Published: (2023)

Comorbidities and outcomes of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a real-world, nationwide, retrospective study from Hungary
by: Peter Batar, et al.
Published: (2024)